✦ LIBER ✦

Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout

✍ Scribed by Michael E. Ernst; Michelle A. Fravel

Book ID: 113544107
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 178 KB
Volume: 31
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2009.11.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Febuxostat: A Selective Xanthine Oxidase

Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout

✍ Bruce, S. P 📂 Article 📅 2006 🏛 Harvey Whitney Books Company 🌐 English ⚖ 150 KB

Pharmacokinetics and Pharmacodynamics of

Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX‐67), a Non‐Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia

✍ Komoriya, K.; Hoshide, S.; Takeda, K.; Kobayashi, H.; Kubo, J.; Tsuchimoto, M.; 📂 Article 📅 2004 🏛 Taylor and Francis Group 🌐 English ⚖ 97 KB

Pharmacokinetics and Pharmacodynamics of

Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX-67), a Non-Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia

✍ K. Komoriya; S. Hoshide; K. Takeda; H. Kobayashi; J. Kubo; M. Tsuchimoto; T. Nak 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 9 KB 👁 1 views

Febuxostat: a non-purine, selective inhi

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

✍ Schumacher Jr, H Ralph 📂 Article 📅 2005 🏛 Informa plc 🌐 English ⚖ 275 KB

Efficacy and Safety of Febuxostat, a Nov

Efficacy and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Kidney Transplant Recipients

✍ Tojimbara, T.; Nakajima, I.; Yashima, J.; Fuchinoue, S.; Teraoka, S. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 203 KB

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal